Observational Study of Biomarkers in Adults With Moderate to Severe Ulcerative Colitis Treated With Targeted Therapies

What this Trial Is About

Ulcerative colitis UC is a long-lasting inflammatory bowel disease that mainly affects adults aged 30 to 40. It causes recurring inflammation in the colon and can lead to disability and lower quality of life. Researchers are studying how to better predict which treatments will work for each patient by identifying new biomarkers in blood, stool, and tissue samples. This study focuses on moderate to severe UC and aims to personalize treatment by understanding early responses to therapy. Participants in this observational study have moderate to severe UC and are starting treatment with biological or small molecule therapies such as anti-TNF, anti-IL1223, anti-integrin agents, or JAK inhibitors. The study involves collecting samples through blood draws, stool collection, and endoscopic biopsies to analyze biomarkers. These procedures occur alongside regular care and assessments to monitor disease activity and treatment response. During the study, researchers will track clinical responses, remission rates, mucosal healing, and symptom improvements at multiple time points up to 52 weeks. They will also observe disease progression, patient-reported outcomes, and long-term complications up to 104 weeks. Participants will undergo standard evaluations including endoscopy and laboratory tests as part of their care and study assessments. The study expects to help guide more personalized treatment choices based on biomarker findings.

A Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies